The companies are not playing by the same rules as the pharma industry — and that's putting patients at risk.
If you're not already a STAT+ subscriber, we're offering a special holiday deal: Get your first three months for just $10. Sign up today. |
|
|
 Eros Dervishi for STAT
Medical marijuana companies are using pharma's sales tactics with little of the same scrutiny Several of the largest medical marijuana companies, like Trulieve, Curaleaf, and Verano, are advertising their products as treatments not just for muscle aches, but for major medical conditions like cancer and depression, without evidence to back up those claims. Read more. By Nicholas Florko |
|
 Caitlin O'Hara for STAT
'We've exhausted all avenues': A small biotech may give up on its ultra-rare disease drug over frustration with FDA Stealth BioTherapeutics has spent the past decade developing and testing a drug for Barth syndrome called elamipretide, in hopes of convincing the FDA to approve it for a tiny population that numbers no more than 130 to 150 patients around the country, including 1-year-old Declan Comerford (above). But Stealth has had an especially trying time seeking FDA approval for its drug. Read more. By Ed Silverman
 Mike Reddy for STAT
In the U.S., scientists see barriers to the development of CAR-T therapies. In Spain, a hospital brews its own Under a special European policy, a CAR-T developed by Hospital Clínic de Barcelona experts had won regulatory approval in Spain and was reimbursed by the national health system like other authorized medications. Read more. By Andrew Joseph
More great reads from STAT this week |
|
Check out more exclusive coverage with a STAT+ subscription | Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles. |
|
| STAT, 1 Exchange Place, Boston, MA | ©2023, All Rights Reserved. | |
|
No comments